<DOC>
	<DOCNO>NCT00042536</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness drug yohimbine naltrexone treat men erectile dysfunction ( ED ) ( inability achieve maintain penile erection satisfactory sexual performance ) . ED medical psychological problem usually associate increased age . Evidence suggest specific neurotransmitter system involve regulation sexual function . Yohimbine naltrexone drug may influence neurotransmitter system . This study use different dos yohimbine fix dos naltrexone determine effectiveness treat ED . Participants study screen medical history , physical examination , blood urine test , electrocardiogram ( ECG ) . The study consist three outpatient visists .</brief_summary>
	<brief_title>Effects Yohimbine Naltrexone Sexual Function</brief_title>
	<detailed_description>Erectile dysfunction ( ED ) relevant medical psychological problem male , usually associate increased age . There substantial evidence available suggest noadrenergic opiate transmitter system involve regulation sexual function . The objective present study evaluate effect safety potential novel treatment combination ED consisting , alpha-adrenoreceptor antagonist yohimbine , opiate antagonist naltrexone . The study use three-phase , double-blind , placebo-controlled cross-over design . Healthy , male volunteer participate . The effect differ dosage yohimbine ( 10 mg versus 20 mg ) fix dose naltrexone ( 50 mg ) penile tumescene rigidity , sexual arousal assess placebo-controlled design . The anticipated risk study consider minimal relation importance increase knowledge regulation physiological psychological aspect regulation sexual function dysfunction . This novel treatment combination could later also apply patient ED different origin , e.g . organic , psychogenic , mixed cause .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>INCLUSION CRITERIA Subjects must medically healthy free mental illness , take medication , must report problem sexual function . They require sexually active , include successful penetrative sexual intercourse act . For assessment sexual function study subject require complete detailed daily diary record erectile activity 7 day first study session , 7 day completion study . EXCLUSION CRITERIA Persons take antidepressant medication likely alter monoamine neurochemistry cerebrovascular cardiovascular function within 6 month prior study exclude . Individuals also exclude : ) evidence axis I psychiatric disorder ( DSMIV criterion ) , b ) medical neurological illness likely affect physiology anatomy , c ) history drug ( include BZDs ) alcohol abuse within 1 year lifetime history alcohol drug dependence ( DSM IV criterion ) , ) smoker , e ) diagnosis sexual disorder , f ) criminal history . Persons must exhibit moderate alcohol use . Persons current previous regular use ( 4 week ) BZDs excessive use alcohol ( 8 ounces/day ) past presence ineligible participate , drug use confound result . Individuals beyond age 50 excluded subject beyond age 50 far great likelihood showing subtile , albeit clinical irrelevant disturbance erectile function .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>Yohimbine</keyword>
	<keyword>Naltrexone</keyword>
	<keyword>Sexual Function</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Alpha-2 Adrenoreceptor</keyword>
	<keyword>Opiate Receptor</keyword>
	<keyword>Male Impotence</keyword>
	<keyword>ED</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
	<keyword>Normal Control</keyword>
</DOC>